Particle.news
Download on the App Store
9 ARTICLES
·
yesterday

Eli Lilly to Acquire Verve Therapeutics for $1.3 Billion

Expected to close in the third quarter of 2025, the deal secures Lilly’s control of VERVE-102, a Fast Track–designated gene-editing therapy in Phase 1b trials.

Eli Lilly will pay as much as $13.50 per share, the companies said Tuesday.
Image
Image
Image

Overview

  • Lilly has struck a definitive agreement to acquire Boston-based Verve for $10.50 per share in cash plus up to $3 per share in contingent value rights, valuing the deal at up to $1.3 billion.
  • The deal, slated to close in the third quarter of 2025, will bring Verve’s lead gene-editing candidate, VERVE-102, fully under Lilly’s control following a 2023 research collaboration.
  • VERVE-102 is in a Phase 1b clinical trial for atherosclerotic cardiovascular disease; it holds FDA Fast Track designation.
  • Verve has advanced three in vivo gene-editing programs; early trials showed significant reductions in LDL cholesterol.
  • The acquisition underscores Lilly’s push to diversify its cardio portfolio beyond chronic therapies; it positions the company for long-term growth as key drug patents approach expiration.